AMG 334
Phase 2Small molecule
AMG 334 is one of 12 small molecule programs targeting Headache. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Flushing
#DrugCompanyPhaseTrials
1Xylocaine
MMEDRx USA, Inc.
Approved
Niacor
AbbViePhase 3
Botulinum Toxin a
GSKApproved
Hcg
Changchun GeneScience Pharmaceutical Co., Ltd.Approved
Heparin Sodium
BBaxter Healthcare Corporation
Phase 3
BG00012
BiogenPhase 3
Nitrostat
VViatris Specialty LLC
Phase 2
Alphagan
AbbViePhase 1
Bayer Aspirin
BayerPreclinical
AMG 334
DDanish Headache Center
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AMG 334. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDanish Headache Center